ROS1 S1986F

CI-VAR-00004016Explore in graph →CIViC 1671

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
ROS1 S1986F	Crizotinib	Predictive	C	Supports Resistance	3	submitted	EID7686 In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC) PMID 29333528 · Gainor et al., 2017 · Open in CIViC	civic
ROS1 S1986F	Crizotinib	Predictive	D	Supports Resistance	—	submitted	EID4807 In an in vitro study, a Ba/F3 cell line expressing S1986F mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 116 nM), as compared… (full text at CIViC) PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.